BR112012012151A2 - lipossoma de irinotecano ou seu cloridrato e seu método de preparação - Google Patents
lipossoma de irinotecano ou seu cloridrato e seu método de preparaçãoInfo
- Publication number
- BR112012012151A2 BR112012012151A2 BR112012012151A BR112012012151A BR112012012151A2 BR 112012012151 A2 BR112012012151 A2 BR 112012012151A2 BR 112012012151 A BR112012012151 A BR 112012012151A BR 112012012151 A BR112012012151 A BR 112012012151A BR 112012012151 A2 BR112012012151 A2 BR 112012012151A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydrochloride
- preparation
- liposome
- irinotecan
- irinotecan liposome
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 4
- 229960004768 irinotecan Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 239000002502 liposome Substances 0.000 abstract 3
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
lipossoma e irinotecano ou seu cloridrato e seu método de preparação. a presente invenção refere-se a um lipossoma de irinotecano ou seu cloridrato e seu método de preparação. o lipossoma compreende irinotecano ou seu cloridrato, foslolipídio neutro e colesterol, em que a razão em peso de colesterol para fosfolipídio neutro é de 1:3-5. o dito lipossoma é preparado pelo método de gradiente iônico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2009/075298 WO2011066684A1 (zh) | 2009-12-03 | 2009-12-03 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012012151A2 true BR112012012151A2 (pt) | 2016-04-12 |
| BR112012012151B1 BR112012012151B1 (pt) | 2021-01-19 |
| BR112012012151B8 BR112012012151B8 (pt) | 2021-05-25 |
Family
ID=44114598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012012151A BR112012012151B8 (pt) | 2009-12-03 | 2009-12-03 | lipossoma de irinotecano ou cloridrato de irinotecano, método de preparação do mesmo, bem como injeção de lipossoma e processo de preparação da mesma |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20120282325A1 (pt) |
| EP (1) | EP2508170B1 (pt) |
| JP (1) | JP5645954B2 (pt) |
| KR (2) | KR101780915B1 (pt) |
| CN (1) | CN102271659B (pt) |
| AU (1) | AU2009356132B2 (pt) |
| BR (1) | BR112012012151B8 (pt) |
| CA (1) | CA2782911C (pt) |
| CY (1) | CY1116811T1 (pt) |
| DK (1) | DK2508170T3 (pt) |
| ES (1) | ES2547698T3 (pt) |
| HK (1) | HK1159482A1 (pt) |
| HR (1) | HRP20150911T1 (pt) |
| HU (1) | HUE027467T2 (pt) |
| MX (1) | MX2012005775A (pt) |
| PL (1) | PL2508170T3 (pt) |
| PT (1) | PT2508170E (pt) |
| RU (1) | RU2526114C2 (pt) |
| SI (1) | SI2508170T1 (pt) |
| SM (1) | SMT201500245B (pt) |
| WO (1) | WO2011066684A1 (pt) |
| ZA (1) | ZA201203316B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102935066B (zh) * | 2011-08-16 | 2014-09-17 | 齐鲁制药有限公司 | 一种伊立替康脂质体制剂及其制备方法 |
| KR20220141906A (ko) | 2011-10-21 | 2022-10-20 | 셀라토 파마슈티칼즈, 인코포레이티드 | 동결건조된 리포좀 |
| KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
| CA2869984C (en) * | 2012-04-10 | 2021-08-17 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CN102697720B (zh) * | 2012-06-29 | 2014-01-15 | 海南灵康制药有限公司 | 盐酸伊立替康脂质纳米粒注射剂 |
| CN103181898B (zh) * | 2012-11-23 | 2016-03-09 | 杭州师范大学 | 一种奥沙利铂脂质体及其应用 |
| EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
| CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
| PT3138555T (pt) | 2014-04-30 | 2020-12-15 | Fujifilm Corp | Composição lipossómica e método de produção da mesma |
| US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
| CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP2017008047A (ja) * | 2015-06-25 | 2017-01-12 | 参天製薬株式会社 | 注射剤 |
| CA2992789A1 (en) | 2015-08-20 | 2017-02-23 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| KR102714060B1 (ko) | 2015-08-21 | 2024-10-08 | 입센 바이오팜 리미티드 | 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 |
| MA42991A (fr) * | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd | Stabilisation de compositions pharmaceutiques de camptothécine |
| CN107281102A (zh) * | 2016-04-11 | 2017-10-24 | 江苏竞诺择生物医药科技有限公司 | 一种用于结直肠肿瘤治疗的药物微粒组合物 |
| CN107456456A (zh) * | 2016-06-03 | 2017-12-12 | 江苏恒瑞医药股份有限公司 | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 |
| JP6878473B2 (ja) * | 2016-06-28 | 2021-05-26 | キメリックス インコーポレイテッド | ブリンシドフォビルの製剤 |
| CN106109415B (zh) * | 2016-07-26 | 2019-01-29 | 金华市人民医院 | 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用 |
| MX2019002733A (es) * | 2016-09-09 | 2019-08-29 | Irisys Inc | Composiciones anticancerígenas liposomales. |
| GEP20217244B (en) * | 2016-10-28 | 2021-04-26 | Ag Novartis | Liposomal formulation for use in the treatment of cancer |
| MX2019004783A (es) * | 2016-11-02 | 2019-08-12 | Ipsen Biopharm Ltd | Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina). |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| CN109675047B (zh) * | 2019-01-07 | 2020-12-04 | 中国科学院化学研究所 | 一种对具有游离羟基的化合物进行脂质体修饰的方法 |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US11273124B2 (en) * | 2019-05-23 | 2022-03-15 | Brown University | Antifungal nanoparticles for targeted treatment of fungal infections |
| CN114177278A (zh) * | 2021-10-18 | 2022-03-15 | 山东多美康生物医药有限公司 | 脂质体制备 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
| ATE238039T1 (de) * | 1998-09-16 | 2003-05-15 | Alza Corp | In liposomen eingeschlossene topoisomerase inhibitoren |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| KR101462819B1 (ko) * | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| ES2594621T3 (es) * | 2004-06-01 | 2016-12-21 | Kabushiki Kaisha Yakult Honsha | Preparación de irinotecán |
| CN1326525C (zh) * | 2004-11-26 | 2007-07-18 | 复旦大学 | 10－羟基喜树碱长循环脂质体及其冻干制剂 |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| CN101517506B (zh) * | 2006-07-17 | 2011-11-30 | 欣达公司 | 计算和预测发电机组的性能 |
| CN101019834A (zh) * | 2006-12-31 | 2007-08-22 | 西安力邦医药科技有限责任公司 | 注射用7－乙基－10羟基喜树碱脂质体的制备方法 |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CA2681302C (en) | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Proliposomal and liposomal compositions of poorly water-soluble compounds |
| CN101283983A (zh) * | 2007-10-26 | 2008-10-15 | 南京长澳医药科技有限公司 | 一种稳定的喜树碱类药物脂质体组合物 |
-
2009
- 2009-12-03 KR KR1020167033432A patent/KR101780915B1/ko active IP Right Grant
- 2009-12-03 AU AU2009356132A patent/AU2009356132B2/en not_active Ceased
- 2009-12-03 SI SI200931279T patent/SI2508170T1/sl unknown
- 2009-12-03 MX MX2012005775A patent/MX2012005775A/es active IP Right Grant
- 2009-12-03 DK DK09851784.0T patent/DK2508170T3/en active
- 2009-12-03 PL PL09851784T patent/PL2508170T3/pl unknown
- 2009-12-03 HU HUE09851784A patent/HUE027467T2/en unknown
- 2009-12-03 KR KR1020127015958A patent/KR20120089754A/ko active Application Filing
- 2009-12-03 CN CN2009801540269A patent/CN102271659B/zh active Active
- 2009-12-03 RU RU2012123875/15A patent/RU2526114C2/ru active
- 2009-12-03 JP JP2012541296A patent/JP5645954B2/ja not_active Expired - Fee Related
- 2009-12-03 EP EP09851784.0A patent/EP2508170B1/en active Active
- 2009-12-03 CA CA2782911A patent/CA2782911C/en active Active
- 2009-12-03 US US13/512,048 patent/US20120282325A1/en not_active Abandoned
- 2009-12-03 BR BR112012012151A patent/BR112012012151B8/pt not_active IP Right Cessation
- 2009-12-03 PT PT98517840T patent/PT2508170E/pt unknown
- 2009-12-03 WO PCT/CN2009/075298 patent/WO2011066684A1/zh active Application Filing
- 2009-12-03 ES ES09851784.0T patent/ES2547698T3/es active Active
-
2011
- 2011-12-28 HK HK11113962.4A patent/HK1159482A1/xx unknown
-
2012
- 2012-05-08 ZA ZA2012/03316A patent/ZA201203316B/en unknown
-
2015
- 2015-09-01 HR HRP20150911TT patent/HRP20150911T1/hr unknown
- 2015-10-09 SM SM201500245T patent/SMT201500245B/xx unknown
- 2015-10-21 CY CY20151100943T patent/CY1116811T1/el unknown
-
2017
- 2017-03-21 US US15/464,922 patent/US10022365B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012012151A2 (pt) | lipossoma de irinotecano ou seu cloridrato e seu método de preparação | |
| NI201400036A (es) | Compuestos con actividad nematicida | |
| BR112012010706A2 (pt) | composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio | |
| DOP2014000090A (es) | Compuestos con actividad nematicida | |
| BR112012007085B8 (pt) | processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila | |
| CU20130137A7 (es) | Derivados de ácido 3- fenilpropiónico ramificados y su uso | |
| BR112013000537A2 (pt) | composição aquosa contendo bromexina | |
| CL2013001287A1 (es) | Glucocorticoides para tratar, mejorar o profilaxis de los efectos adversos neurológicos causados por un diminio de unión cd3; kit que comprende un gc y un dominio de unión cd3 y las instrucciones. | |
| BRPI0915536A2 (pt) | salicilatos acetilados de ácidos graxos e seus usos | |
| BR112012007109A2 (pt) | bifidobacterium longum atcc baa-999 (bl-999) e controle de peso | |
| CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BRPI0913537A2 (pt) | método para o tratamento de objetos de acordo com o seu peso individual | |
| CU20120099A7 (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| BR112013017845A2 (pt) | agente antidiabético de abaixamento de lipídio | |
| EA201190242A1 (ru) | Липидные композиции | |
| BR112015002421A2 (pt) | composição farmacêutica ou nutracêutica com características de liberação sustentada e com resistência contra a influência do etanol | |
| BR112012026919A2 (pt) | aglutinantes | |
| BRPI0801697A2 (pt) | trem de pouso para aeronaves | |
| BR112013001109A2 (pt) | composição que contém galacto-oligossacarídeos e método para produzi-la | |
| UY32517A (es) | Derivados de nicotinamida, su preparación y su aplicación en terapéutica | |
| BR112015032276A2 (pt) | composição, cápsula macia, e, inibidor de diminuição da tensão de ruptura | |
| UY32404A (es) | 4-aril-butan-1,3-diamidas | |
| CL2013003093A1 (es) | Composiciones que comprende cation de polihidroxioxoaluminio detectable por rmn; metodo de fabricacion de los mismos; y su uso. | |
| BR112013025696A2 (pt) | composição compreendendo cimento portland para utilização em vertebroplastia | |
| ECSP11011486A (es) | Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |